Antibodies Targeting a Conserved Surface Polysaccharide Are Protective Against a Wide Range of Microbial Pathogens Producing β-1-6-Linked Poly-N-Acetylglucosamine(PNAG)  

作　　者：Xi Lu Guoqing Li Jing Pang Xinyi Yang Colette Cywes-Bentley Xuefu You Gerald B.Pier 

机构地区：[1]Beijing Key Laboratory of Antimicrobial Agents,Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China [2]Division of Infectious Diseases,Department of Medicine,Brigham and Women’s Hospital,Harvard Medical School,Boston,MA 02115,USA

出　　处：《Engineering》2024年第7期69-76,共8页工程（英文）

基　　金：supported by the National Natural Science Foundation of China(32141003 and 81703399);the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS,2021-I2M-1-026).

摘　　要：The b-1-6-linked poly-N-acetylglucosamine(PNAG)polymer is a conserved surface polysaccharide produced by many bacteria,fungi,and protozoan(and even filarial)parasites.This wide-ranging expression makes PNAG an attractive target for vaccine development,as it potentially encompasses a broad range of microorganisms.Significant progress has been made in discovering important properties of the biology of PNAG expression in recent years.The molecular characterization and regulation of operons for the production of PNAG biosynthetic proteins and enzymes have been studied in many bacteria.In addition,the physiological function of PNAG has been further elucidated.PNAG-based vaccines and PNAG-targeting antibodies have shown great efficacy in preclinical research.Furthermore,clinical tests for both vaccines and antibodies have been carried out in humans and economically important animals,and the results are promising.Although it is not destined to be a smooth road,we are optimistic about new vaccines and immunotherapeutics targeting PNAG becoming validated and eventually licensed for clinical use against multiple infectious agents.

关 键 词：Poly-N-acetylglucosamine Conjugate vaccine Monoclonal antibody 

分 类 号：R96[医药卫生—药理学]